Lipocine to Present Phase 2 LPCN 1148 Data at EASL Congress 2024

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company based in Salt Lake City, announced on May 8, 2024, that data from its Phase 2 study of LPCN 1148 will be presented at the European Association for the Study of Liver (EASL) Congress. This prestigious event will take place from June 5 to 8, 2024, in Milan, Italy.

LPCN 1148 is a drug currently under evaluation by Lipocine for the management of decompensated cirrhosis. The medication comprises testosterone laurate (TL) and aims to address several unmet needs of patients suffering from cirrhosis. The company believes that LPCN 1148 has the potential to improve sarcopenia and quality of life, prevent or reduce the occurrence of decompensation events such as hepatic encephalopathy (HE), and enhance post-liver transplant outcomes, survival rates, and healthcare costs.

Lipocine is dedicated to leveraging its proprietary technology platform to enhance therapeutics through effective oral delivery. The company's focus is on developing differentiated products for central nervous system (CNS) disorders and other significant medical needs. Lipocine has a range of drug candidates in development and is exploring partnership opportunities for further advancement.

The company's clinical development pipeline includes several promising candidates. LPCN 1154 is an oral formulation of brexanolone being developed for the potential treatment of postpartum depression. Another candidate, LPCN 2101, is targeted for the treatment of epilepsy. LPCN 2203 is an oral medication aimed at managing essential tremor, while LPCN 2401 combines an anabolic androgen receptor agonist with α-tocopherol, an antioxidant, to aid in chronic weight management as an adjunct therapy to incretin mimetics.

LPCN 1148, a novel androgen receptor agonist prodrug, is designed for oral administration to manage symptoms associated with liver cirrhosis, including the prevention of overt hepatic encephalopathy recurrence. Lipocine is also exploring partnerships for other drug candidates, including LPCN 1107 for the prevention of preterm birth, LPCN 1144 for the treatment of non-cirrhotic nonalcoholic steatohepatitis (NASH), and LPCN 2401 for obesity management.

One of Lipocine's notable achievements is the approval of TLANDO by the FDA. TLANDO is a novel oral prodrug of testosterone containing testosterone undecanoate, developed for adult males with hypogonadism, a condition associated with a deficiency of endogenous testosterone.

The announcement highlighted that the presentation of LPCN 1148 data at the EASL Congress underscores the potential significance of this medication in addressing the needs of patients with decompensated cirrhosis. The company is optimistic about the potential uses and benefits of LPCN 1148 and is committed to advancing its development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!